Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the ...

The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...

Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart ...

On the heels of a data readout suggesting one of its cancer drugs could become a future blockbuster, Zymeworks is adopting a ...

The deal gives J&J access to a pipeline of drugs designed to “hold and kill” tumors, led by a prostate cancer medicine that’s ...

The new fund will mostly support biotechs making new drugs, with investments spanning from initial financings to follow-on ...

Artios Pharma, which looking for newer targets that, like PARP inhibitors, affect the way tumors fix themselves, said its ...

After multiple clinical setbacks and layoff rounds, Mersana accepted an offer in which the bulk of the payouts will only ...

Korro’s lead program for alpha-1 antitrypsin deficiency wasn’t as potent as anticipated, leading the company to change course ...

The alliance extends a deal streak in genetic medicine for Lilly and hands the company rights to an experimental treatment ...

The drug appears effective against both “relapsing” and “primary progressive” forms of the disease, though some analysts ...

The decision, issued without the input of an official advisory committee, revises long-held labeling on the drugs cautioning ...